Emerging Cell-Based Immunotherapies
08
Aug
-
09
Aug
2023
When
Boston

USA
Where

Up until now, the cell therapy industry has been driven by the remarkable success of CAR T therapy. However, many believe the future of immunotherapy lies with other cell types such as NKs, Gamma Deltas, B Cells, TILs, and B cells, which offer many advantages over CAR T therapies and are attracting the attention of big pharma and investors. Cambridge Healthtech Institute’s 2nd Annual Emerging Cell-Based Immunotherapies conference brings together leading researchers and companies to discuss the latest developments in cellular therapies such as NK cells, TILs, Gamma Deltas, Myeloid Cell, B Cell therapies, iPSCs, and more. Topics include novel engineering approaches, preclinical and clinical updates, efforts against solid tumors, combination therapies, and the latest approaches to improve persistence, safety, and efficacy.

Similar Events

You May Like

Event

Cambridge Healthtech Institute

0/5
(0)

Cambridge Healthtech Institute – Your Life Science Network Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.

08 - 09 Aug 2023
In-Person

Speakers and Delegates
Industry Experts and Thought Leaders

Chief Executive Officer
Chief Scientific Officer
Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, Assistant Professor
Director, Immunotherapy / Preclinical Development
Chief Executive Officer & Co-Founder
Chief Executive Officer
Senior Director, Head of Cell Therapy
Executive Director
Professor
President and CEO
Assistant Professor of Medicine

Sponsors and Exhibitors
Brand, Media and Promotional Partners

Biocytogen

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.

FUJIFILM Pharmaceuticals U.S.A., Inc.

Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost. FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILM’s global center for new drug development.

Sanyou Biopharmaceuticals Co., Ltd.

Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.

Genscript Probio

The CDMO segment of the world's leading biotech company GenScript.

Telesis Bio

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity’s greatest challenges.

OmniAb, Inc.

The OmniAb discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.

Selvita

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

Nona Biosciences

Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal

BostonGene

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in

NeoSome Life Sciences

NeoSome Life Sciences is a PreClinical Research Organization providing in life modeling for several therapeutic research areas. We offer a range of services from Proof of Concept to IND enabling studies. Our specialties include Infectious Diseases, O

Organizer

Get emails from us

Thank you
Oops! Something went wrong